The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Study: Association of Patient Demographic Characteristics, Insurance Status With Survival in Cancer Patients
The objective of the study was to examine whether positive treatment effects in cancer randomized clinical trials apply to specific demographic or insurance subgroups.
Combination Therapy Significantly Improved Progression-Free Survival in Patients with HER2-Positive Breast Cancer
There are few effective treatment options for patients with HER2-positive breast cancer who have received 2 or more previous therapies for advanced disease, according to the study authors.
According to new research, biomarkers that signal whether a patient's cancer treatment may be harming their heart have been identified.
Researchers have discovered a natural protective mechanism that leads to the programmed death of potentially diseased cancer cells.
In a lecture at the virtual Community Oncology Conference 2020, Christine Roussel discussed some clinical considerations for the use of medical cannabis in patients with cancer.
Study Finds No Overall Survival Benefit in Patients With Advanced BRCA-Mutated Breast Cancer Receiving Talazoparib
Research confirms earlier studies that found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile.
There are a variety of interventions that can be used to improve survival after a patient reports cancer toxicity following treatment.
LGBTQ patients with cancer face specific barriers when seeking medical care, but pharmacists and other medical professionals can take specific steps to reduce care gaps.
An expert panel at the Community Oncology Conference 2020 discussed how COVID-19 is changing the future of community oncology.
New research has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.
Sacituzumab govitecan-hziy is the first antibody-drug conjugates approved by the FDA specifically for relapsed or refractory metastatic triple-negative breast cancer (TNBC).
Cancer cells avoid an immune system attack after radiation by taking control of a cell signaling pathway that helps dying cells avoid triggering an immune response.